Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria avium-intracellulare, quantification

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87562 refers to a laboratory test designed for the detection of the infectious agent Mycobacteria avium-intracellulare (MAI) through the analysis of nucleic acids, specifically DNA or RNA. Mycobacteria avium-intracellulare is part of the Mycobacteria avium complex (MAC), which consists of two species of gram-positive, acid-fast, atypical bacteria that are often indistinguishable from one another. These bacteria are commonly found in environmental sources such as water and soil, and they can also be carried by birds and farm animals. Infections caused by MAI primarily affect the lungs and can lead to a range of symptoms including a productive cough with significant sputum production, fever, weight loss, fatigue, and night sweats. The testing process involves a direct probe test that identifies a unique nucleic acid sequence, known as the target sequence, of the MAI organism if it is present in various biological samples such as blood, tissue, cerebrospinal fluid (CSF), or synovial fluid. This probe is labeled with either fluorescent or chemiluminescent markers to facilitate detection. The sample undergoes treatment to release nucleic acids from the target organism, allowing the labeled probe to specifically bind to the matching target sequence, forming a stable hybrid. Ribosomal RNA is typically the focus of these tests due to its abundance in microorganisms, as it exists in thousands of copies compared to the limited copies found in genomic DNA. To enhance the sensitivity of the assay, an amplified probe technique is employed, which involves exponentially multiplying the target sequence of MAI DNA or RNA into millions of copies. The most prevalent amplification methods include polymerase chain reaction (PCR) and reverse transcriptase polymerase chain reaction (RT-PCR). Following amplification, the replicated sequences are identified using labeled DNA probes. The quantification aspect of this test, as indicated by CPT® Code 87562, provides an assessment of the number of microorganisms present in the sample. Quantitative or real-time PCR is often utilized to amplify the isolated nucleic acid segment, generating reports that document the absolute or relative amounts of the known nucleic acid sequence at each stage of the testing process.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 87562 is indicated for the detection and quantification of Mycobacteria avium-intracellulare (MAI) in patients who may be experiencing symptoms associated with MAI infection. The following conditions and symptoms warrant the use of this laboratory test:

  • Respiratory Symptoms: Patients presenting with a productive cough that produces large amounts of sputum.
  • Fever: Persistent or recurrent fever that may accompany respiratory symptoms.
  • Weight Loss: Unexplained weight loss that may be associated with chronic infection.
  • Fatigue: Significant fatigue that is not attributable to other causes.
  • Night Sweats: Episodes of excessive sweating during the night, which can be a sign of infection.

2. Procedure

The procedure for CPT® Code 87562 involves several critical steps to ensure accurate detection and quantification of Mycobacteria avium-intracellulare. The process begins with the collection of a biological sample, which may include blood, tissue, cerebrospinal fluid (CSF), or synovial fluid. Once the sample is obtained, it undergoes treatment to release nucleic acids from any present MAI organisms. This step is crucial as it prepares the sample for the subsequent detection process.

  • Sample Preparation: The biological sample is treated to lyse cells and release nucleic acids, ensuring that any target sequences from the MAI organism are accessible for detection.
  • Probe Hybridization: A labeled probe, which is specific to the target nucleic acid sequence of MAI, is introduced to the sample. This probe is designed to bind only to the unique sequences of the MAI organism, forming a stable hybrid if the target is present.
  • Amplification of Nucleic Acids: To enhance the sensitivity of the test, an amplification technique such as polymerase chain reaction (PCR) or reverse transcriptase polymerase chain reaction (RT-PCR) is employed. This process exponentially increases the number of copies of the target nucleic acid, making it easier to detect.
  • Detection of Amplified Sequences: After amplification, the replicated nucleic acid sequences are identified using labeled DNA probes. This step confirms the presence of MAI in the sample.
  • Quantification: The final step involves quantifying the amplified nucleic acid sequences. This is typically achieved through quantitative or real-time PCR, which provides a report detailing the absolute or relative amounts of the target nucleic acid sequence, thus assessing the quantity of MAI present in the sample.

3. Post-Procedure

After the completion of the procedure associated with CPT® Code 87562, the laboratory will analyze the results and generate a report detailing the presence and quantity of Mycobacteria avium-intracellulare in the sample. Clinicians will review these results to determine the appropriate course of action for the patient, which may include further diagnostic testing, treatment options, or monitoring of the patient's condition. It is essential for healthcare providers to communicate the results to the patient and discuss any necessary follow-up care or additional testing that may be required based on the findings. Additionally, proper documentation of the procedure and results is crucial for compliance and billing purposes.

Short Descr M.AVIUM-INTRA DNA QUANT
Medium Descr IADNA MYCOBACTERIA AVIUM-INTRACELLULARE QUANT
Long Descr Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria avium-intracellulare, quantification
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
Date
Action
Notes
2011-01-01 Changed Short description changed.
1998-01-01 Added First appearance in code book in 1998.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"